Premium
CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma
Author(s) -
Toyoda Miroru,
Kaira Kyoichi,
Shino Masato,
Sakakura Koichi,
Takahashi Katsumasa,
Takayasu Yukihiro,
Tominaga Hideyuki,
Oriuchi Noboru,
Nikkuni Osamu,
Suzuki Masami,
Iijima Misa,
Tsukamoto Norifumi,
Nagamori Shushi,
Kanai Yoshikatsu,
Oyama Tetsunari,
Chikamatsu Kazuaki
Publication year - 2015
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23797
Subject(s) - stage (stratigraphy) , basal cell , medicine , oncology , carcinoma , biology , paleontology
Background Both L‐type amino acid transporter 1 (LAT1) and CD98 are strongly expressed in primary human cancer and play essential roles in tumor growth. We studied the clinicopathological significance of LAT1 and CD98 expression in hypopharyngeal squamous cell carcinoma (SCC). Methods A total of 70 patients with stage III/IV disease were retrospectively reviewed. Immunohistochemical staining of tumor sections was used to examine LAT1, CD98, Ki‐67, CD34, and p53. Results High LAT1 and CD98 expression were noted in 60.0% and 47.1%, respectively ( p = .174). A statistically significant correlation was recognized between LAT1 and CD98 expression and both expressions were closely associated with tumor cell proliferation. Although LAT1 expression was not significantly associated with poor survival, multivariate analysis revealed high CD98 expression to be an independent prognostic factor for predicting a poor outcome. Conclusion CD98 is a promising prognostic marker for predicting outcomes after surgical treatment in patients with advanced hypopharyngeal SCC. © 2014 Wiley Periodicals, Inc. Head Neck 37: 1569–1574, 2015